Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial.

Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, Aledort LM, George JN, Kessler CM, Sanz MA, Liebman HA, Slovick FT, de Wolf JT, Bourgeois E, Guthrie TH Jr, Newland A, Wasser JS, Hamburg SI, Grande C, Lefrère F, Lichtin AE, Tarantino MD, Terebelo HR, Viallard JF, Cuevas FJ, Go RS, Henry DH, Redner RL, Rice L, Schipperus MR, Guo DM, Nichol JL.

Lancet. 2008 Feb 2;371(9610):395-403. doi: 10.1016/S0140-6736(08)60203-2.

PMID:
18242413
2.

Romiplostim in chronic immune thrombocytopenic purpura.

Cersosimo RJ.

Clin Ther. 2009 Sep;31(9):1887-907. doi: 10.1016/j.clinthera.2009.09.013. Review.

PMID:
19843480
3.

Romiplostim for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a single technology appraisal.

Mowatt G, Boachie C, Crowther M, Fraser C, Hernández R, Jia X, Ternent L.

Health Technol Assess. 2009 Sep;13 Suppl 2:63-8. doi: 10.3310/hta13suppl2/09. Review.

4.

Romiplostim: a review of its use in immune thrombocytopenia.

Keating GM.

Drugs. 2012 Feb 12;72(3):415-35. doi: 10.2165/11208260-000000000-00000. Review.

PMID:
22316355
5.

Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura.

Jamali F, Lemery S, Ayalew K, Robottom S, Robie-Suh K, Rieves D, Pazdur R.

Oncology (Williston Park). 2009 Jul;23(8):704-9.

6.

Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study.

Tarantino MD, Bussel JB, Blanchette VS, Despotovic J, Bennett C, Raj A, Williams B, Beam D, Morales J, Rose MJ, Carpenter N, Nie K, Eisen M.

Lancet. 2016 Jul 2;388(10039):45-54. doi: 10.1016/S0140-6736(16)00279-8.

PMID:
27103127
7.

Eltrombopag for the treatment of chronic idiopathic (immune) thrombocytopenic purpura (ITP).

Boyers D, Jia X, Crowther M, Jenkinson D, Fraser C, Mowatt G.

Health Technol Assess. 2011 May;15 Suppl 1:23-32. doi: 10.3310/hta15suppl1/03. Review.

8.

The treatment for primary immune thrombocytopenia with romiplostim in adult and paediatric patients: use experience at a Spanish university hospital.

Marquínez-Alonso I, Escudero-Vilaplana V, Pernía S, Beléndez Bieler C, Fernández-Llamazares CM, Sanjurjo-Sáez M.

J Clin Pharm Ther. 2014 Aug;39(4):376-82. doi: 10.1111/jcpt.12156.

PMID:
24702274
9.

Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial.

Shirasugi Y, Ando K, Miyazaki K, Tomiyama Y, Okamoto S, Kurokawa M, Kirito K, Yonemura Y, Mori S, Usuki K, Iwato K, Hashino S, Wei H, Lizambri R.

Int J Hematol. 2011 Jul;94(1):71-80. doi: 10.1007/s12185-011-0886-8.

PMID:
21706145
10.

Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag.

Chouhan JD, Herrington JD.

Pharmacotherapy. 2010 Jul;30(7):666-83. doi: 10.1592/phco.30.7.666. Review.

PMID:
20575632
11.

A phase II, open-label, sequential-cohort, dose-escalation study of romiplostim in Japanese patients with chronic immune thrombocytopenic purpura.

Shirasugi Y, Ando K, Hashino S, Nagasawa T, Kurata Y, Kishimoto Y, Iwato K, Ohtsu T, Berger DP.

Int J Hematol. 2009 Sep;90(2):157-65. doi: 10.1007/s12185-009-0361-y.

PMID:
19543952
12.

An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP).

Shirasugi Y, Ando K, Miyazaki K, Tomiyama Y, Iwato K, Okamoto S, Kurokawa M, Kirito K, Hashino S, Ninomiya H, Mori S, Yonemura Y, Usuki K, Wei H, Lizambri R.

Int J Hematol. 2012 Jun;95(6):652-9. doi: 10.1007/s12185-012-1065-2.

PMID:
22532046
13.

Romiplostim: a breakthrough treatment for the management of immune thrombocytopenic purpura.

Newland A.

Eur J Haematol Suppl. 2009 Mar;(71):20-5. doi: 10.1111/j.1600-0609.2008.01209.x. Review.

PMID:
19200304
14.

A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia.

Bussel JB, Buchanan GR, Nugent DJ, Gnarra DJ, Bomgaars LR, Blanchette VS, Wang YM, Nie K, Jun S.

Blood. 2011 Jul 7;118(1):28-36. doi: 10.1182/blood-2010-10-313908.

15.

Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP.

Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL.

Blood. 2009 Mar 5;113(10):2161-71. doi: 10.1182/blood-2008-04-150078. Erratum in: Blood. 2009 May 7;113(19):4822.

16.

AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP.

Bussel JB, Kuter DJ, George JN, McMillan R, Aledort LM, Conklin GT, Lichtin AE, Lyons RM, Nieva J, Wasser JS, Wiznitzer I, Kelly R, Chen CF, Nichol JL.

N Engl J Med. 2006 Oct 19;355(16):1672-81. Erratum in: N Engl J Med. 2006 Nov 9;355(19):2054.

17.

Romiplostim.

Frampton JE, Lyseng-Williamson KA.

Drugs. 2009;69(3):307-17. doi: 10.2165/00003495-200969030-00006. Review.

PMID:
19275274
18.

Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura.

Stasi R, Evangelista ML, Amadori S.

Drugs. 2008;68(7):901-12. Review.

PMID:
18457458
19.

Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials.

George JN, Mathias SD, Go RS, Guo M, Henry DH, Lyons R, Redner RL, Rice L, Schipperus MR.

Br J Haematol. 2009 Feb;144(3):409-15. doi: 10.1111/j.1365-2141.2008.07464.x.

PMID:
19016720
20.

Romiplostim management of immune thrombocytopenic purpura.

Ipema HJ, Jung MY, Lodolce AE.

Ann Pharmacother. 2009 May;43(5):914-9. doi: 10.1345/aph.1L643. Review.

PMID:
19401474
Items per page

Supplemental Content

Support Center